NASDAQ:RGNX REGENXBIO (RGNX) Stock Price, News & Analysis $14.33 -0.06 (-0.42%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$14.16▼$14.7750-Day Range$10.59▼$15.9952-Week Range$10.49▼$28.80Volume318,287 shsAverage Volume638,509 shsMarket Capitalization$705.90 millionP/E RatioN/ADividend YieldN/APrice Target$38.58 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get REGENXBIO alerts: Email Address REGENXBIO MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside169.2% Upside$38.58 Price TargetShort InterestBearish9.76% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.38Based on 7 Articles This WeekInsider TradingSelling Shares$548,687 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.37) to ($2.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.22 out of 5 starsMedical Sector167th out of 936 stocksBiological Products, Except Diagnostic Industry18th out of 154 stocks 3.4 Analyst's Opinion Consensus RatingREGENXBIO has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageREGENXBIO has only been the subject of 2 research reports in the past 90 days.Read more about REGENXBIO's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted9.76% of the outstanding shares of REGENXBIO have been sold short.Short Interest Ratio / Days to CoverREGENXBIO has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in REGENXBIO has recently increased by 11.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldREGENXBIO does not currently pay a dividend.Dividend GrowthREGENXBIO does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreREGENXBIO has received a 71.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for REGENXBIO is -0.82. Previous Next 3.0 News and Social Media Coverage News SentimentREGENXBIO has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for REGENXBIO this week, compared to 4 articles on an average week.Search Interest3 people have searched for RGNX on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows5 people have added REGENXBIO to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, REGENXBIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $548,687.00 in company stock.Percentage Held by Insiders13.13% of the stock of REGENXBIO is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.08% of the stock of REGENXBIO is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about REGENXBIO's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for REGENXBIO are expected to grow in the coming year, from ($4.37) to ($2.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of REGENXBIO is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of REGENXBIO is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioREGENXBIO has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about REGENXBIO's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About REGENXBIO Stock (NASDAQ:RGNX)REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.Read More RGNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGNX Stock News HeadlinesJuly 19, 2024 | insidertrades.comKenneth T. Mills Sells 2,210 Shares of REGENXBIO Inc. (NASDAQ:RGNX) StockJuly 4, 2024 | insidertrades.comArgeris N. Karabelas Sells 10,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) StockJuly 27, 2024 | Porter & Company (Ad)My grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.July 25 at 7:05 AM | prnewswire.comREGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational HighlightsJuly 22, 2024 | markets.businessinsider.comRBC Capital Remains a Buy on RegenXBio (RGNX)July 18, 2024 | americanbankingnews.comBrokerages Set REGENXBIO Inc. (NASDAQ:RGNX) Price Target at $38.58June 24, 2024 | investorplace.com7 Biotech Stocks to Buy on the Dip: June 2024June 24, 2024 | prnewswire.comREGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger PatientsJuly 27, 2024 | Porter & Company (Ad)My grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.June 18, 2024 | prnewswire.comREGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS IIJune 12, 2024 | prnewswire.comREGENXBIO Announces Leadership TransitionJune 10, 2024 | seekingalpha.comRegenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong BuyJune 5, 2024 | prnewswire.comREGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 25, 2024 | finance.yahoo.comIt Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The MicroscopeMay 15, 2024 | markets.businessinsider.comEvaluating Regenxbio: Insights From 9 Financial AnalystsMay 11, 2024 | finance.yahoo.comAnalysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest ResultsMay 10, 2024 | finance.yahoo.comRegenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS ForecastsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid FinancialsSee More Headlines Receive RGNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RGNX CUSIPN/A CIK1590877 Webwww.regenxbio.com Phone(240) 552-8181FaxN/AEmployees370Year FoundedN/APrice Target and Rating Average Stock Price Target$38.58 High Stock Price Target$55.00 Low Stock Price Target$21.00 Potential Upside/Downside+169.2%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($5.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-263,490,000.00 Net Margins-299.96% Pretax Margin-300.14% Return on Equity-70.72% Return on Assets-41.30% Debt Debt-to-Equity RatioN/A Current Ratio3.59 Quick Ratio3.59 Sales & Book Value Annual Sales$90.24 million Price / Sales7.82 Cash FlowN/A Price / Cash FlowN/A Book Value$7.09 per share Price / Book2.02Miscellaneous Outstanding Shares49,260,000Free Float42,789,000Market Cap$705.90 million OptionableOptionable Beta1.26 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Kenneth T. Mills (Age 49)President, CEO & Director Comp: $1.02MMr. Vittal K. Vasista (Age 56)Executive VP & CFO Comp: $671.41kMr. Curran M. Simpson M.S. (Age 62)Executive VP & COO Comp: $677.7kDr. Olivier Danos Ph.D. (Age 66)Executive VP & Chief Scientific Officer Comp: $728.06kDr. Stephen Pakola M.D. (Age 55)Executive VP & Chief Medical Officer Comp: $673.76kMr. Patrick J. Christmas II (Age 53)J.D., Executive VP & Chief Legal Officer Comp: $1.11MMs. Shiva G. FritschChief Communications & People OfficerDr. Laura A. Coruzzi J.D. (Age 70)Ph.D., Executive Vice President of Intellectual Property Dr. Ram Palanki Pharm.D. (Age 47)Executive VP of Commercial Strategy & Operations More ExecutivesKey CompetitorsAlectorNASDAQ:ALECC4 TherapeuticsNASDAQ:CCCCuniQureNASDAQ:QUREBlack Diamond TherapeuticsNASDAQ:BDTXCompugenNASDAQ:CGENView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 28,846 shares on 7/26/2024Ownership: 0.689%Kenneth T MillsSold 12,221 sharesTotal: $168,405.38 ($13.78/share)Louisiana State Employees Retirement SystemBought 2,800 shares on 7/24/2024Ownership: 0.046%Hennion & Walsh Asset Management Inc.Bought 27,906 shares on 7/20/2024Ownership: 0.272%Assenagon Asset Management S.A.Bought 588,773 shares on 7/18/2024Ownership: 1.657%View All Insider TransactionsView All Institutional Transactions RGNX Stock Analysis - Frequently Asked Questions How have RGNX shares performed this year? REGENXBIO's stock was trading at $17.95 on January 1st, 2024. Since then, RGNX stock has decreased by 20.2% and is now trading at $14.33. View the best growth stocks for 2024 here. How were REGENXBIO's earnings last quarter? REGENXBIO Inc. (NASDAQ:RGNX) posted its earnings results on Wednesday, May, 8th. The biotechnology company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.28) by $0.10. The company's revenue for the quarter was down 18.3% on a year-over-year basis. What is Ken Mills' approval rating as REGENXBIO's CEO? 3 employees have rated REGENXBIO Chief Executive Officer Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among the company's employees. Who are REGENXBIO's major shareholders? Top institutional shareholders of REGENXBIO include Assenagon Asset Management S.A. (1.66%), Bank of New York Mellon Corp (0.69%), Hennion & Walsh Asset Management Inc. (0.27%) and Harbor Capital Advisors Inc. (0.05%). Insiders that own company stock include Kenneth T Mills, Kenneth T Mills, Vittal Vasista, Steve Pakola, Argeris N Karabelas and Allan M Fox. View institutional ownership trends. How do I buy shares of REGENXBIO? Shares of RGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of REGENXBIO own? Based on aggregate information from My MarketBeat watchlists, some other companies that REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Pfizer (PFE). This page (NASDAQ:RGNX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
